Articles producció científica> Medicina i Cirurgia

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

  • Datos identificativos

    Identificador: PC:1742
    Autores:
    Luis MasanaMarina CuchelEric BruckertHenry N. GinsbergFrederick J. RaalRaul D. SantosRobert A. HegeleJan Albert KuivenhovenBørge G. NordestgaardOlivier S. DescampsElisabeth Steinhagen-ThiessenAnne Tybjærg-HansenGerald F. WattsMaurizio AvernaCatherine BoileauJan BorénAlberico L. CatapanoJoep C. DefescheG. Kees HovinghSteve E. HumphriesPetri T. KovanenPaïivi PajukantaKlaus G. ParhoferKausik K. RayAnton F. H. StalenhoefErik StroesMarja-Riitta TaskinenAlbert WiegmanOlov WiklundM. John Chapman
    Resumen:
    Filiació URV: SI
  • Otros:

    Autor según el artículo: Luis Masana; Marina Cuchel; Eric Bruckert; Henry N. Ginsberg; Frederick J. Raal; Raul D. Santos; Robert A. Hegele; Jan Albert Kuivenhoven; Børge G. Nordestgaard; Olivier S. Descamps; Elisabeth Steinhagen-Thiessen; Anne Tybjærg-Hansen; Gerald F. Watts; Maurizio Averna; Catherine Boileau; Jan Borén; Alberico L. Catapano; Joep C. Defesche; G. Kees Hovingh; Steve E. Humphries; Petri T. Kovanen; Païivi Pajukanta; Klaus G. Parhofer; Kausik K. Ray; Anton F. H. Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Albert Wiegman; Olov Wiklund; M. John Chapman
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: MASANA MARÍN, LUIS; Marina Cuchel; Eric Bruckert; Henry N. Ginsberg; Frederick J. Raal; Raul D. Santos; Robert A. Hegele; Jan Albert Kuivenhoven; Børge G. Nordestgaard; Olivier S. Descamps; Elisabeth Steinhagen-Thiessen; Anne Tybjærg-Hansen; Gerald F. Watts; Maurizio Averna; Catherine Boileau; Jan Borén; Alberico L. Catapano; Joep C. Defesche; G. Kees Hovingh; Steve E. Humphries; Petri T. Kovanen; Païivi Pajukanta; Klaus G. Parhofer; Kausik K. Ray; Anton F. H. Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Albert Wiegman; Olov Wiklund; M. John Chapman
    Palabras clave: Homozygous familial hypercholesterolaemia Diagnosis Statins
    Resumen: Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH. Methods and results: Early diagnosis ofHoFHand prompt initiation of diet and lipid-lowering therapy are critical. Genetic testing may provide a definitive diagnosis, but if unavailable, markedly elevated LDL-C levels together with cutaneous or tendon xanthomas before 10 years, or untreated elevated LDL-C levels consistent with heterozygous FH in both parents, are suggestive of HoFH.We recommend that patients with suspected HoFH are promptly referred to specialist centres for a comprehensiveACVDevaluation and clinical management. Lifestyle intervention and maximal statin therapy are the mainstays of treatment, ideally started in the first year of life or at an initial diagnosis, often with ezetimibe and other lipid-modifying therapy. As patients rarely achieve LDL-C targets, adjunctive lipoprotein apheresis is recommended where available, preferably started by age 5 and no later than 8 years. The number of therapeutic approaches has increased following approval of lomitapide and mipomersen for HoFH. Given the severity of ACVD, we recommend regular follow-up, including Doppler echocardiographic evaluation of the heart and aorta annually, stress testing and, if available, computed tomography coronary angiography every 5 years, or less if deemed necessary. Conclusion: This EAS Consensus Panel highlights the need for early identification of HoFH patients, prompt referral to specialized centres, and early initiation of appropriate treatment. These recommendations offer guidance for a wide spectrum of clinicians who are often the first to identify patients with suspected HoFH.
    Grupo de investigación: Unitat de Recerca de Lípids i Arteriosclerosi
    Áreas temáticas: Ciències de la salut Ciencias de la salud Health sciences
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 1016-5169
    Identificador del autor: N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D
    Fecha de alta del registro: 2016-06-20
    Página final: 14
    Volumen de revista: 43
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://academic.oup.com/eurheartj/article/35/32/2146/2481389
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI del artículo: 10.1093/eurheartj/ehu274
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2015
    Página inicial: 1
    Tipo de publicación: Article Artículo Article
  • Palabras clave:

    Hipercolesterolèmia
    Aterosclerosi
    Homozygous familial hypercholesterolaemia
    Diagnosis
    Statins
    Ciències de la salut
    Ciencias de la salud
    Health sciences
    1016-5169
  • Documentos:

  • Cerca a google

    Search to google scholar